Iclaprim injection: Phase II data

In an evaluator-blind, European Phase II trial in 92 patients, clinical cure rates at TOC were 92.9% and 90.3% for the 0.8 and 1.6 mg/kg doses twice-daily doses of iclaprim, respectively, compared wit...